APLS | tickerfilter.com

Fundamental analysis

46%

Profitability 36%

Dept financing 36%

Liquidity 75%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.06%

1 Month

-11.97%

3 Months

-15.95%

6 Months

-29.40%

1 Year

-23.62%

2 Year

-68.21%

Key data

Stock price

$19.86

P/E Ratio

134.71

DAY RANGE

$19.54 - $20.32

EPS

$0.18

52 WEEK RANGE

$16.10 - $30.48

52 WEEK CHANGE

-$21.56

MARKET CAP

3.178 B

YIELD

N/A

SHARES OUTSTANDING

127.830 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

0.91

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,297,946

AVERAGE 30 VOLUME

$2,103,870

Company detail

CEO: Cedric Francois
Region: US
Website: apellis.com
Employees: 770
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Apellis Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

APLS - Apellis Pharmaceuticals, Inc.